JAK inhibitors

Half of severe alopecia patients on upadacitinib hit 80% scalp coverage by week 24

The JAMA Dermatology results published August 12 push an already-approved arthritis pill toward a new indication, which turns interesting science into a prior-authorization question about who counts as a responder.